Atlas Trials

Mosunetuzumab With or Without Polatuzumab Vedotin and Obinutuzumab for the Treatment of Untreated Indolent B-Cell Non-Hodgkin Lymphoma

Clinical trial NCT05169658 · COMPLETED

Trial details

NCT number
NCT05169658
Sponsor
University of Washington
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Non-Hodgkin LymphomaGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3a Follicular LymphomaIndolent B-Cell Non-Hodgkin LymphomaMarginal Zone LymphomaRecurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRefractory Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Start date
2022-03-23
Primary completion
2025-04-02
Enrollment
42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.